Displaying drugs 6751 - 6775 of 8037 in total
AZD-1386
AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).
Investigational
Matched Description: … NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of …
Sofituzumab vedotin
Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Investigational
Matched Description: … Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of …
Zetomipzomib
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
Investigational
Matched Description: … Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate …
Crovalimab
Crovalimab is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).
Investigational
Matched Description: … clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of …
Giroctocogene fitelparvovec
Giroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
Investigational
Matched Description: … fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of …
Revusiran
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
Investigational
Matched Description: … Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of …
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
Talditercept alfa
Talditercept alfa is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).
Investigational
Matched Description: … investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of …
ICG-136
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
Matched Description: … It was investigated for the treatment of acute myeloid leukemia. …
LuLym-T
LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Investigational
Matched Description: … LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. …
Mozafancogene autotemcel
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Matched Description: … Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of …
ENTR-601-44
ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Matched Description: … Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy …
IMMU-114
IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Investigational
Matched Description: … IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
DDP-225
DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a...
Investigational
Matched Description: … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the ... The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered …
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … these have met the requirements of an ideal oral drug candidate. ... excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of …
Loprazolam
Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence...
Experimental
Matched Description: … It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. ... It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or …
Olokizumab
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome....
Investigational
Matched Description: … immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of …
RH-1
RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.
Experimental
Investigational
Matched Description: … RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma …
GlycoPEG-GCSF
GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Investigational
Matched Description: … GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of …
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Matched Description: … TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia …
Thiorphan
A potent inhibitor of membrane metalloendopeptidase (enkephalinase). Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms.
Experimental
Matched Description: … A potent inhibitor of membrane metalloendopeptidase (enkephalinase). …
Dexetimide
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Matched Description: … Benzetimide is the (-)-enantimorph of dexetimide. …
Rapastinel
Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).
Investigational
Matched Description: … Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive …
VTP-194204
Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung Cancer.
Investigational
Matched Description: … Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung …
Displaying drugs 6751 - 6775 of 8037 in total